<DOC>
	<DOC>NCT00804934</DOC>
	<brief_summary>The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.</brief_summary>
	<brief_title>Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis</brief_title>
	<detailed_description>To determine mean change in visual acuity at 6 and 12 months</detailed_description>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability to provide written informed consent and comply with study assessments for the full duration of the study Age greater then and equal 50 years Patients with active neovascular AMD Received at least 3 treatments with antiVEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months If the patient has bilateral disease and qualifies for the study, both eyes may be included Subjects who meet any of the following criteria will be excluded from this study: Pregnancy or lactation Premenopausal women not using adequate contraception. Participation in another simultaneous medical investigation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>